Dipyridamole combined with immunoglobulin and aspirin in the treatment of Kawasaki disease in children: a meta-analysis - Takeaways - MDSpire

Dipyridamole combined with immunoglobulin and aspirin in the treatment of Kawasaki disease in children: a meta-analysis

  • By

  • Yanshuo Shi

  • Xin Xu

  • Yuanyuan Yue

  • Jianqun Zhao

  • Kaiqing Yao

  • Huizhen Wu

  • June 29, 2026

  • 0 min

Share

  • 1

    The study evaluates the efficacy and safety of dipyridamole combined with immunoglobulin and aspirin for treating Kawasaki disease in children.

  • 2

    Eighteen randomized controlled trials involving 1,594 patients were included in the meta-analysis.

  • 3

    The observation group showed a significantly higher total effective rate compared to the control group.

  • 4

    Clinical symptom improvement and laboratory indicators were significantly better in the observation group.

  • 5

    There was no significant difference in adverse reaction incidence between the two treatment groups.

Original Source(s)

Dipyridamole combined with immunoglobulin and aspirin in the treatment of Kawasaki disease in children: a meta-analysis

  • by Yanshuo Shi, Xin Xu, Yuanyuan Yue, Jianqun Zhao, Kaiqing Yao, Huizhen Wu

  • June 29, 2026

Related Content

Persistently increased frequency of diabetic ketoacidosis in new-onset type 1 diabetes in Polish children: nationwide analysis 2019–2022

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Auricular therapy as adjunctive treatment for pediatric attention deficit hyperactivity disorder: a scoping review